Figure 3. OPN/αvβ3 activated β-catenin via PI3K/Akt/GSK3β signaling pathway.

A. MV4-11 was treated by various amount of recombinant human OPN for 24 hours, then β-catenin was detected by Western blot assay. B. MV4-11 was pretreated by αvβ3 blocking antibody (1μg/ml) for 2 hours, then treated by OPN (1.2 μg/ml) for another 24 hours. The phosphorylation level of Akt and GSK3β and the expression of β-catenin were measured by Western blot analysis. C. MV4-11 was pretreated by PI3K inhibitor LY294002 (25μM) for 2 hours, then treated by OPN (1.2 μg/ml) for another 24 hours. The phosphorylation level of Akt and GSK3β and the expression of β-catenin were measured by Western blotting analysis.